Friday, May 16, 2008 New Green Baron Stock Pick to be Released on Wednesday, May 21st New Pick will be Fourth Green Baron Selection for Year 2008; BB Stock Below $1.00 Per Share The Green Baron Report will release its fourth fully profiled stock pick for 2008 and 69th pick since inception on Wednesday, May 21 at 1:30 pm EST / 10:30 am PST. Our new pick is traded on the OTC Bulletin Board under $1 per share. We have extremely solid fundamental reasons to own it now, and we believe this stock will be widely followed very soon. Be sure to mark your calendars! Our booth exhibit at The Money Show in Las Vegas was a huge success. We calculate that we have just added over 600 new members to receive The Green Baron Report. We thank all current members for coming by to say hello as well.
Stock Pick Update Znomics, Inc. (BB: ZNOM) New Interview with CEO Richard Sessions Now Available The Green Baron Report Conducts Exclusive Webcast with Znomics, Inc. The Green Baron Report is proud to make available a very insightful interview with Znomics, Inc. CEO Richard Sessions. During this exclusive interview, CEO Richard Sessions describes in detail the potential of Znomics. The company, headquartered in Portland, Oregon, is a biotechnology company using proprietary zebrafish technology to find new drugs and drug targets for complex human diseases. The Company is developing a novel drug discovery methodology based on high throughput drug screening against human disease models in live zebrafish. This methodology screens against all potential drug targets in the animal and improves the speed and efficacy of finding lead compounds compared with single target screens predominantly used in the pharmaceutical industry. The Green Baron Report believes that Znomics has developed an outstanding platform to accelerate the discovery of new compounds and medicines to treat specific disorders and diseases. The Company has structured material transfer agreements that secure potential rewards of any significant research finding from more than 100 top universities and research facilities. ZNOM stock should begin to react very soon as new investors realize its limitless potential, and as the Company’s experienced internal research team releases promising new research discoveries. LOS ANGELES - May 16, 2008 - The Green Baron Report today announced it has conducted an exclusive audio-taped webcast interview with Richard Sessions, CEO of Znomics, Inc. (OTCBB: ZNOM), with unrestricted access available immediately at www.TheGreenBaron.com. The webcast is also available at www.StrictlyStocks.com, “Where Wall Street speaks to the World.” The Green Baron Report issued its “new stock pick” profile report on Znomics on Monday, May 12. The profile discusses the Znomics technology platform that has lead to collaborative drug discovery programs and more than 100 material transfer agreements with Universities and Institutions. Investors may receive the report without cost at http://www.thegreenbaron.com/Join.htm. About The Green Baron Report The Green Baron Report is a subsidiary of Evergreen Marketing. The Green Baron Report is an internet stock market newsletter that focuses on low priced stock picks that appear to have significant upside potential. For more information about Evergreen Marketing, Inc. and their subsidiary The Green Baron Investors Society visit them on the web at http://www.EvergreenMarketingInc.com and http://www.TheGreenBaron.com or http://www.StrictlyStocks.com. Our disclaimer can be viewed at http://www.thegreenbaron.com/Disclaimer.htm. About Znomics, Inc. Znomics, Inc. is focused on identifying and developing new pharmaceutical products for treatment of human disorders and diseases. The company's drug discovery platform is based on its catalogued library of mutations in the zebrafish, called the ZeneMark Library. The library, the first in a vertebrate, currently contains more than 11,000 strains of fish representing mutations in approximately half of the known genome. Zebrafish share 80%-90% of the same genes as humans. The company is leveraging this technology for its internal drug discovery efforts as well as establishing collaborative partnerships with pharmaceutical companies and universities.
|
